Delivery Order SPE2DB22D9367-SPE2DB24FSV62
Award Date 1/8/24
Potential Completion Date 1/30/24
Potential Value $125K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a ceiling value of $138,073.90 and an ultimate completion date of May 29, 2024. DMS Pharmaceutical Group will provide 3,750 units of the pharmaceutical product ASPARLAS (5 ML vial) to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery...
- The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 3,750 units of the 5 milliliter vial of the pharmaceutical product ASPARLAS. The total potential value of the order is $82,844.34. The contract has a completion date of February 7, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a range of brand and generic prescription and over-the-counter drug supplies to...
- The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of 3,750 units of the pharmaceutical product ASPARLAS in 5 mL vials. The contract has a potential value of $55,229.58 and a completion date of March 13, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA valued at up to $4,999,999, which enables the agency to order a...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The $148,084.30 contract is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS (5 ML vial) with a completion date of July 29, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of medical products to federal agencies, including the DLA. The company holds a significant...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order valued at fifty-two thousand five hundred ninety-nine dollars and sixty cents ($52,599.60) by the Defense Logistics Agency to supply 3,750 units of the pharmaceutical product ASPARLAS 3,750 UNIT/5 ML VIAL 5ML. The delivery order was issued against DMS Pharmaceutical Group's indefinite delivery contract with the Defense Logistics Agency to provide pharmaceuticals and medical supplies with a potential value of up to...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency to supply 3,750 units of ASPARLAS 3,750 UNIT/5 ML VIAL 5ML pharmaceutical products. The delivery order, valued at one hundred five thousand one hundred ninety-nine dollars and twenty cents ($105,199.20), has a completion date of December 27, 2023. No set-aside designation was used for this award. DMS Pharmaceutical Group Inc. will fulfill the...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) under the SPE2DB program. The award, valued at $55,229.58, is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS (5 mL vial). This order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to...
- This is a delivery order award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) for the procurement of 3,750 units of the pharmaceutical product ASPARLAS (5 mL vial). The $105,199.16 firm fixed-price delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999. This IDC, valid through November 2026, enables the DLA to issue delivery orders for a broad range of...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $29,616.86 contract is for the delivery of 3,750 units of the drug ASPARLAS (5 mL vial) with a period of performance through April 18, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $78,899.37 contract is for the delivery of 3,750 units of the drug Asparlas (5 ml vial) with a completion date of November 30, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide...